Alembic Pharmaceuticals
Alembic Pharmaceuticals Limited, commonly referred to as Alembic, is a prominent player in the global pharmaceutical industry, headquartered in Vadodara, India. Established in 1907, the company has a rich history marked by significant milestones, including its expansion into regulated markets and the development of a robust portfolio of generic and branded formulations. Alembic operates primarily in the areas of pharmaceuticals, biotechnology, and active pharmaceutical ingredients (APIs), focusing on therapeutic segments such as cardiovascular, anti-infective, and central nervous system disorders. The company is renowned for its commitment to quality and innovation, which is reflected in its extensive range of products that meet stringent international standards. With a strong market position, Alembic Pharmaceuticals has achieved notable success, including multiple approvals from regulatory authorities worldwide. Its dedication to research and development, coupled with a strategic approach to global expansion, solidifies its reputation as a trusted name in the pharmaceutical sector.
DitchCarbon Score
How does Alembic Pharmaceuticals's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Alembic Pharmaceuticals's score of 60 is higher than 99% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Alembic Pharmaceuticals's reported carbon emissions
In 2023, Alembic Pharmaceuticals reported total greenhouse gas emissions of approximately 909,814,000 kg CO2e. This figure includes 86,096,000 kg CO2e from Scope 1 emissions, 67,544,000 kg CO2e from Scope 2 emissions, and a significant 756,174,000 kg CO2e from Scope 3 emissions. The company has set ambitious climate commitments, aiming for a 63% reduction in absolute greenhouse gas emissions across all scopes by 2034, using 2022 as the base year. Furthermore, Alembic Pharmaceuticals is committed to achieving net-zero emissions by 2050, with a long-term target of reducing emissions by 90% from the same base year. The company has also disclosed emission intensities, reporting 26,000 kg CO2e per tonne of physical output and 9,000 kg CO2e per employee for Scope 1 and 2 emissions. These initiatives align with industry standards and reflect a proactive approach to climate action, demonstrating Alembic Pharmaceuticals' commitment to sustainability and environmental responsibility.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2021 | 2022 | 2023 | |
|---|---|---|---|
| Scope 1 | - | 00,000,000 | 00,000,000 |
| Scope 2 | - | 00,000,000 | 00,000,000 |
| Scope 3 | - | 000,000,000 | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Alembic Pharmaceuticals is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
